Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factors affecting interactions between prion protein isoforms.

B Caughey1, G S Baron

  • 1National Institutes of Health, NIAID, Rocky Mountain Labs, Hamilton, MT 59840, USA.

Biochemical Society Transactions
|August 28, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS<sup>G12C</sup> inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Cross-validation of the RT-QuIC assay for the antemortem detection of chronic wasting disease in elk.

Prion·2020
Same author

A Promising Antiprion Trimethoxychalcone Binds to the Globular Domain of the Cellular Prion Protein and Changes Its Cellular Location.

Antimicrobial agents and chemotherapy·2017
Same author

Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).

Current molecular medicine·2015
Same author

Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds?

Accounts of chemical research·2006
Same author

Prion protein and the molecular features of transmissible spongiform encephalopathy agents.

Current topics in microbiology and immunology·2004
Same journal

TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis.

Biochemical Society transactions·2026
Same journal

Advancing the monitoring of organelle contact sites in vitro and in vivo.

Biochemical Society transactions·2026
Same journal

Mechanisms influencing transient cytoplasmic protein targeting to intracellular lipid droplets.

Biochemical Society transactions·2026
Same journal

Replication associated nuclear DNA mismatch repair across kingdoms.

Biochemical Society transactions·2026
Same journal

Phosphatases of regenerating liver downregulate PTEN to promote tumorigenesis.

Biochemical Society transactions·2026
Same journal

Implications of Rho GTPase signaling in cancer immunotherapy.

Biochemical Society transactions·2026
See all related articles

Prion protein (PrP) conversion is key to transmissible spongiform encephalopathies. Prion propagation between cells requires PrP-res transfer into recipient membranes, and heparan sulfate acts as a cofactor. Therapeutic strategies targeting PrP interactions are being explored.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Molecular Biology

Background:

  • Transmissible spongiform encephalopathies (TSEs) involve interactions between normal prion protein (PrP-sen) and its disease-associated isoform (PrP-res).
  • Understanding PrP-res propagation is crucial for developing treatments for diseases like Creutzfeldt-Jakob disease.

Purpose of the Study:

  • To investigate the mechanism of PrP-res propagation between cells.
  • To identify cofactors involved in PrP conversion.
  • To explore potential therapeutic strategies for inhibiting PrP-res formation.

Main Methods:

  • Cell-free PrP conversion assays were used to study PrP-res formation.
  • Investigated PrP-res conversion in the presence of microsomal and raft membranes.
  • Tested the effect of heparan sulfate on PrP-res formation.

Related Experiment Videos

  • Evaluated small molecules, synthetic peptides, and antibodies for their ability to inhibit PrP-res formation.

    • Main Results:

    • PrP-res propagation between cells requires transfer into recipient cell membranes.
    • Heparan sulfate significantly stimulates PrP-res formation, acting as a cofactor.
    • The antimalarial drug quinacrine inhibits PrP-res formation and is undergoing clinical trials.
    • Various small molecules, peptides, and antibodies also inhibit PrP-res formation, localizing interaction sites.

    Conclusions:

    • Cell-to-cell prion propagation necessitates PrP-res transfer into target cell membranes.
    • Heparan sulfate is a key modulator of PrP-res formation in vivo.
    • Therapeutic interventions targeting PrP-sen/PrP-res interactions show promise for treating prion diseases.